Deep in the Heart of Texas Bio--a Takeover?

Leibs, Anthony
May 1999
Mergers & Acquisitions Report;05/24/99, Vol. 12 Issue 21, p1
Discusses the need of Houston, Texas-based Texas Biotechnology Corp. (TBC) to make an alliance with commercially experienced corporate partner. Business and financial information on TBC; Comments from some industry analysts; Significance of the approval of Novastan, an anti-coagulant drugs produced by TBC, by the United States Food and Drug Administration for the company.


Related Articles

  • LI summit update: Expand LI involvement in international commerce. Crosson, Matthew // Long Island Business News (7/1993 to 5/2009);5/15/95, Vol. 42 Issue 20, p16 

    Reports on a trade show program launched by the New Long Island Partnership in 1995. Program's focus on biotechnology industry; Participation in the Bio International Conference and Exhibition; Value of exports from Long Island.

  • The effects of alliance portfolio characteristics and absorptive capacity on performance A study of biotechnology firms. George, Gerard; Zahra, Shaker A.; Wheatley, Kathleen K.; Khan, Raihan // Journal of High Technology Management Research;Autumn2001, Vol. 12 Issue 2, p205 

    In many high technology industries, strategic alliances have become important for improving a firm's financial performance by providing knowledge that can be used to develop the capabilities needed to introduce new products. Therefore, researchers have examined those characteristics of alliances...

  • Alliances/Collaborations. Holland-Moritz, Pam // Drug Discovery & Development;Jun2003, Vol. 6 Issue 6, p22 

    Reports on alliances and collaborations formed between biotechnology companies involved in drug development. Intronn Inc. and ProBioGen AG; Applied BioPhysics Inc.'s collaborative research with George Plopper at Rensselaer Polytechnic Institute in Troy, New York; Co-marketing agreement between...

  • Big pharma.  // New Internationalist;Sep2002, Issue 349, p19 

    Reports on the formation of alliances by biotechnology companies with the pharmaceutical giants. Profit forecast for gene therapy; Ratio of biotechnology companies manufacturing medicines in 2000; Global sales of plant-based drugs in 1999.

  • Pharma-biotech research alliances increase. Liebman, Milton // Medical Marketing & Media;Dec2002, Vol. 37 Issue 12, p18 

    Focuses on the alliances formed between pharmaceutical companies and biotechnology firms in the U.S. Increase funding for drug development; Expansion of research on cancer and diabetes drugs; Impact of the move on the biotechnology sector.

  • Becoming Partners of Choice. Richardson, Jason; Evangelista, Elio // Pharmaceutical Executive;Nov2002 Supplement, Vol. 22, p12 

    Discusses the pharmaceutical-biotechnology alliances in the U.S. Potential gains and pitfalls of the alliances; Method for maximizing pharma-biotech alliances; Strategies and tactics used by companies to approach pharma-biotech alliances. INSETS: Fruits of Alliance Labors;Pfizer's Partnership...

  • Hope for the Best Prepare for the Worst. Fiscus, Philip W. // Pharmaceutical Executive;Nov2002 Supplement, Vol. 22, p22 

    Explores the alliances between pharmaceutical industry and biotechnology industry in the U.S. Inherent risks in the alliances; Importance of business recovery plans in pharma-biotech alliances; Compliance of the biotech companies to clinical regulatory standards; Examination of a biotech...

  • Biotechnology --- A Challenge for the Modern Contract Manufacturer. Lambert, Rolf // Pharmaceutical Technology Europe;Mar2003 Supplement, Vol. 15, p31 

    Discusses ways to achieve the synergistic cooperation between European contract manufacturing organizations (CMO) and biotechnology firms. Reasons for outsourcing; Services offered by a CMO; Attributes of a good CMO; Gap between the cultures and business methods of biotechnology firms and...

  • Becoming a Partner of Choice and Evaluating Prospective Alliances. Wallis, David; Heybroek, Jan // Pharmaceutical Technology Europe;Aug2003 Supplement, Vol. 15, p18 

    Discusses the concept of alliance in the pharmaceutical and biotechnology industries. Procedure for determining strategic partnering objectives; Importance of assessing a potential partner's capabilities and ability to meet its own strategic needs; Background on due diligence. INSETS: Managing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics